Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo

Enrolling by invitation · Early Phase 1 · Has a placebo group

Conditions studied: Intertrochanteric Femur Fracture, Muscle Atrophy

In brief

The investigators central hypothesis is that metformin supplementation will be well-tolerated, safe, and provide patients with improved functional and muscle morphology outcomes following intertrochanteric femur fracture. The objectives will be tested in older adults that sustain a hip fracture and are randomized to receive a daily oral dose (1.5g daily) of metformin or a non-active placebo during 4 months of recovery following surgery.

Key facts

Study ID
NCT07179042
Run by
University of Utah
People needed
60
Starts
2025-09-04
Expected to finish
2030-09-01
Last updated by the study team
2026-04-29

Who can join

Age: 60 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.